EntreMed to Present at the Rodman and Renshaw 10th Annual Healthcare Conference
November 07 2008 - 7:00AM
PR Newswire (US)
ROCKVILLE, Md., Nov. 7 /PRNewswire-FirstCall/ -- EntreMed, Inc.
(NASDAQ: ENMD) a clinical-stage pharmaceutical company developing
therapeutics for the treatment of cancer and inflammatory diseases,
announced today that James S. Burns, President and Chief Executive
Officer, will present a Company update at the Rodman and Renshaw
10th Annual Healthcare Conference, which is being held November
10-12, 2008 at the New York Palace Hotel in New York, NY. Mr.
Burns' presentation is scheduled for Tuesday, November 11, 2008 at
2:25 p.m. (local time). Mr. Burns' presentation will be web cast
and, as previously announced, will serve as the Company's third
quarter 2008 update. The presentation can be accessed through the
Company's web site at http://www.entremed.com/. An archive will be
available on the web site for approximately 90 days. About EntreMed
EntreMed, Inc. is a clinical-stage pharmaceutical company
developing therapeutic candidates primarily for the treatment of
cancer and inflammation. MKC-1, an oral cell-cycle regulator with
activity against the mTOR pathway, is currently in multiple Phase 2
clinical trials for cancer. ENMD-2076, a selective angiogenic
kinase inhibitor, and ENMD-1198, a novel antimitotic agent are in
Phase 1 studies in advanced cancers. The Company also has an
approved IND application for Panzem(R) in rheumatoid arthritis.
EntreMed's goal is to develop and commercialize new compounds based
on the Company's expertise in angiogenesis, cell cycle regulation,
cell signaling and inflammation - processes vital to the treatment
of cancer and other diseases, such as rheumatoid arthritis.
Additional information about EntreMed is available on the Company's
web site at http://www.entremed.com/ and in various filings with
the Securities and Exchange Commission. Forward Looking Statements
This release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act with respect to the
outlook for expectations for future financial or business
performance (including the timing of royalty revenues and future
R&D expenditures), strategies, expectations and goals.
Forward-looking statements are subject to numerous assumptions,
risks and uncertainties, which change over time. Forward-looking
statements speak only as of the date they are made, and no duty to
update forward-looking statements is assumed. Actual results could
differ materially from those currently anticipated due to a number
of factors, including those set forth in Securities and Exchange
Commission filings under "Risk Factors," including risks relating
to the need for additional capital and the uncertainty of
additional funding; variations in actual sales of Thalomid(R),
risks associated with the Company's product candidates; the
early-stage products under development; results in preclinical
models are not necessarily indicative of clinical results,
uncertainties relating to preclinical and clinical trials; success
in the clinical development of any products; dependence on third
parties; future capital needs; and risks relating to the
commercialization, if any, of the Company's proposed products (such
as marketing, safety, regulatory, patent, product liability,
supply, competition and other risks). CONTACT: Ginny Dunn Associate
Director Corporate Communications & Investor Relations
EntreMed, Inc. 240-864-2643 DATASOURCE: EntreMed, Inc. CONTACT:
Ginny Dunn, Associate Director of Corporate Communications &
Investor Relations, EntreMed, Inc., +1-240-864-2643 Web Site:
http://www.entremed.com/
Copyright